High-Performance Liquid Chromatography (HPLC)

This current study focuses on the impact of Artificial Intelligence (AI) on the rapid identification of new molecules to suppress aging processes, which increases the proportion of healthspan relative to lifespan. The research approach taken involved a quantitative method, where artificial intelligence-based machine learning, bioinformatics, and statistical analysis were used alongside computational molecular docking. Biochemical information from databases such as PubChem, DrugBank, and ChEMBL was leveraged to screen and analyze molecular data. It was observed that AI-assisted predictive models, especially Deep Learning Neural Networks, offered highly accurate predictions concerning the biological activity of anti-aging compounds. The selected molecules showed considerable decreases in oxidative stress, inflammation, and cellular senescence markers, coupled with improved mitochondrial function and cell repair. Moreover, quantitative results showed that the use of AI for predicting the efficacy of anti-aging agents led to more significant healthspan enhancements than lifespan increases.

The technology and ability of 3D printing have transformed the sphere of personalized medicine, allowing manufacturing of the customized drug delivery to address diverse needs of a specific patient with regard to physiologic, pharmacokinetically, and therapeutically oriented preferences. This review generates a pharmaceutics-oriented view of the use of novel 3D printing technologies such as the Fused Deposition Modeling (FDM), Stereolithography (SLA), and inkjet printing in the development of personalized dosage forms comprising of oral tablets, implants, microneedles, and transdermal patches. Animal model experimental preclinical research, such as that in rabbits, rats, and mice, has proven the capability of the technologies to perform zero order release and controlled release of drugs, the capability to release multiple drugs using staggered kinetics, and to provide site-specific or minimally invasive delivery. The results support the benefits of structural flexibility, programmable release profiles, and improved patient adherence, especially in the case of complex conditions and important vulnerable groups of patients (pediatric and geriatric). But there are still some impediments on the way to clinical application, such as thermal instability of labile drugs, biocompatibility issues, poor reproducibility in device operation, a lack of standard regulatory frameworks, and insufficient long-term safety documentation. The review ends with a purpose of identifying the future research and development directions that include the necessity of the use of superior biocompatible materials, inherent hybrid printing methods and scalability in production, as well as interdisciplinary cooperation to enable clinical translation and redefine the future of personalized drug treatment.